➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKinsey
Medtronic
Boehringer Ingelheim
Harvard Business School

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,375,404


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,375,404
Title:Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Abstract: A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin.RTM. formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).
Inventor(s): Vranderick; Manon (St-Lazare, CA), St-Onge; Jean-Luc (Mirabel, CA), Gedeon; Christelle (Toronto, CA), Gallo; Michele (Blainville, CA), Gervais; Eric (Blainville, CA)
Assignee: Duchesnay Inc. (Blainville, CA)
Application Number:14/746,635
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,375,404
Patent Claims: 1. An oral dosage form comprising: (A) a core comprising: (a) from about 5 mg to about 20 mg of doxylamine and/or a pharmaceutically acceptable salt thereof; and (b) from about 5 mg to about 20 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof; (B) an enteric coating substantially surrounding the core; and (C) one or more outer coatings substantially surrounding the enteric coating, the one or more outer coatings comprising: (a) from about 5 mg to about 20 mg of doxylamine and/or a pharmaceutically acceptable salt thereof; and (b) from about 5 mg to about 20 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof.

2. The oral dosage form of claim 1, wherein the core comprises about 10 mg of doxylamine and/or a pharmaceutically acceptable salt thereof.

3. The oral dosage form of claim 1, wherein the core comprises about 10 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof.

4. The oral dosage form of claim 1, wherein the one or more outer coatings comprise about 10 mg of doxylamine and/or a pharmaceutically acceptable salt thereof.

5. The oral dosage form of claim 1, wherein the one or more outer coatings comprise about 10 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof.

6. The oral dosage form of claim 1, wherein the core comprises doxylamine succinate.

7. The oral dosage form of claim 1, wherein the one or more outer coatings comprise doxylamine succinate.

8. The oral dosage form of claim 2, wherein the core comprises doxylamine succinate.

9. The oral dosage form of claim 4, wherein the one or more outer coatings comprise comprises doxylamine succinate.

10. The oral dosage form of claim 1, wherein the core comprises pyridoxine hydrochloride.

11. The oral dosage form of claim 1, wherein the one or more outer coatings comprise pyridoxine hydrochloride.

12. The oral dosage form of claim 3, wherein the core comprises pyridoxine hydrochloride.

13. The oral dosage form of claim 5, wherein the one or more outer coatings comprise pyridoxine hydrochloride.

14. The oral dosage form of claim 1, wherein the one or more outer coatings comprise a first outer coating and a second outer coating.

15. The oral dosage form of claim 14, wherein the first outer coating comprises the doxylamine and/or pharmaceutically acceptable salt thereof, and the second outer coating comprises the pyridoxine and/or a pharmaceutically acceptable salt thereof.

16. The oral dosage form of claim 1, comprising: (A) a core comprising: (a) about 10 mg of doxylamine succinate; and (b) about 10 mg of pyridoxine hydrochloride; (B) an enteric coating substantially surrounding the core; and (C) one or more outer coatings substantially surrounding the enteric coating, the one or more outer coatings comprising: (a) about 10 mg of doxylamine succinate; and (b) about 10 mg of pyridoxine hydrochloride.

17. The oral dosage form of claim 1, comprising: (A) a core comprising: (a) about 10 mg of doxylamine succinate; and (b) about 10 mg of pyridoxine hydrochloride; (B) an enteric coating substantially surrounding the core; and (C) two outer coatings substantially surrounding the enteric coating, the two outer coatings comprising: (a) a first outer coating comprising about 10 mg of pyridoxine hydrochloride; and (b) a second outer coating comprising about 10 mg of doxylamine succinate.

18. A method for alleviating the symptoms of nausea and vomiting in a mammal, said method comprising administering the oral dosage form of claim 1 to a mammal in need thereof.

19. A method for alleviating the symptoms of nausea and vomiting of human pregnancy, said method comprising administering the oral dosage form of claim 1 to a pregnant human female in need thereof.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Dow
Boehringer Ingelheim
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.